کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3343420 | 1214418 | 2009 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
ایمونولوژی، آلرژی و روماتولوژی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Aromatase inhibitor (AI) therapy significantly increases the disease-free survival in postmenopausal patients with hormone receptor-positive breast cancer. AIs are potent inhibitors of oestradiol production. Large adjuvant trials showed that the third-generation AIs (i.e., anastrozole, letrozole and exemestane) are risk factors for an increased bone loss, and are associated with an increase in the risk of fractures in women with bone fragility. A comprehensive assessment of risk of fractures must be performed at the initiation of an AI therapy. Antiresorptive drugs (i.e., bisphosphonates and denosumab) are effective for bone loss prevention and treatment in these patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Best Practice & Research Clinical Rheumatology - Volume 23, Issue 6, December 2009, Pages 805–811
Journal: Best Practice & Research Clinical Rheumatology - Volume 23, Issue 6, December 2009, Pages 805–811
نویسندگان
Mirieme Ghazi, Christian Roux,